pharmacotherapy of schizophrenia: ploypharmacy approaches

Personalised approaches to pharmacotherapy for schizophrenia

Personalised medicine has been defined as the ‘use of genetic or other biomarker information to improve the safety, effectiveness, and health outcomes of patients via more efficiently targeted risk strati fication, prevention, and tailored medication and treatment management approaches’ (Faulkner 2012). It is a novel approach to therapeutic decisionmaking, which has particular relevance and pot...

Approaches to improve adherence to pharmacotherapy in patients with schizophrenia

PURPOSE In patients with schizophrenia, nonadherence to prescribed medications increases the risk of patient relapse and hospitalization, key contributors to the costs associated with treatment. The objectives of this review were to evaluate the impact of nonadherence to pharmacotherapy in patients with schizophrenia as it relates to health care professionals, particularly social workers, and t...

pharmacotherapy of schizophrenia

traditionally, schizophrenia was considered to be a severe psychiatric disorder, with a chronic course and an unfavorable outcome. throughout history, there has been incidence of schizophrenia, roughly one percent of the population, consistently, in every culture. it is generally acknowledged that schizophrenia has multifactorial etiology, with multiple susceptibility genes interacting with env...

Pharmacotherapy for treatment-resistant schizophrenia

Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are gener...

REVIEW Pharmacotherapy of Schizophrenia in Germany

The practice of pharmacotherapy of schizophrenia in Germany is based both on clinical experience and research findings. Experience and studies emphasize that neuroleptic medication is severely limited by side effects including acute extrapyramidal syndromes and tardive dyskinesia. Comparing neuroleptic doses in both acute and maintenance therapy have clinicians encouraged to evaluate methods fo...

Recent approaches to pharmacotherapy of personality disorders